Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241756 | 0.87 | GRM1 (0.72) | GRM1GRM5 | |
| SCHEMBL8242609 | 0.86 | GRM1 (0.71) | GRM1GRM5 | |
| SCHEMBL8244411 | 0.84 | GRM1 (0.69) | GRM1GRM5 | |
| SCHEMBL8241476 | 0.84 | GRM1 (0.71) | GRM1GRM5 | |
| SCHEMBL8244517 | 0.84 | GRM1 (0.69) | GRM1GRM5 | |
| SCHEMBL13199732 | 0.83 | GRM1 (0.76) | GRM1GRM5 | |
| SCHEMBL12507669 | 0.83 | GRM1 (1.00) | GRM1GRM5 | |
| SCHEMBL13199787 | 0.83 | GRM1 (1.00) | GRM1 | |
| SCHEMBL8244053 | 0.81 | GRM1 (0.77) | GRM1GRM5 | |
| SCHEMBL12507934 | 0.81 | GRM1 (0.79) | GRM1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931683-B1 | FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7767815-B2 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767815-B2 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070072863-A1 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072863-A1 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| WO-2007024593-A1 | FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072863-A1 | Fused tricyclic mGluR1 antagonists as therapeutic agents | GRM1, GRM3, GRIN1 | GRM1 1/4885GRM5 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.